重度抑郁症治疗药物——吉哌隆缓释剂  

Major depressive disorder treatment drug:gepirone extended-release

作　　者：张苏素 宗克丽 刘晓静 阮家俊 张有志 李行舟 胡春[1] ZHANG Susu;ZONG Keli;LIU Xiaojing;RUAN Jiajun;ZHANG Youzhi;LI Xingzhou;HU Chun(Faculty of Pharmaceutical Engineering,Shenyang Pharmaceutical University,Shenyang 110000,China;Institute of Pharmacology&Toxicology of the Academy of Military Medical Sciences,Beijing 100850,China)

机构地区：[1]沈阳药科大学制药工程学院,沈阳110000 [2]军事科学院军事医学研究院毒物药物研究所,北京100850

出　　处：《临床药物治疗杂志》2025年第2期22-26,共5页Clinical Medication Journal

摘　　要：吉哌隆缓释剂是由美国研发的一种5-羟色胺1A(5-HT1A)受体激动剂,于2023年9月经美国FDA批准上市,主要治疗成人重度抑郁症(MDD),也是首个用于治疗成人MDD的口服选择性5-HT1A受体激动剂。临床研究显示,吉哌隆缓释剂与安慰剂相比,可以改善患者的17项汉密尔顿抑郁量表总分,但易引起恶心、头疼等不良反应。本文就吉哌隆缓释剂的基本信息、作用机制、药动学、临床研究等进行概述。Gepirone extended-release agent is a 5-hydroxytryptamin 1A(5-HT1A)receptor agonist developed in the United States.It received approval from the U.S.FDA in September 2023 as the first oral selective 5-HT1A receptor agonist for the treatment of major depressive disorder(MDD)in adults.Clinical studies have demonstrated that,compared to a placebo,gepirone extended-release agent significantly improves the total score on the 17-item Hamilton depression rating scale.However,it may cause common side effects such as nausea and headaches.This article provides a comprehensive overview of the basic information,mechanism of action,pharmacokinetics,and clinical research findings related to gepirone extendedrelease agent.

关 键 词：吉哌隆缓释剂 5-羟色胺1A 激动剂 重度抑郁症 

分 类 号：R971.4[医药卫生—药品]